PD-L1 Negative, Triple Negative Breast Cancer
Conditions
Brief summary
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Interventions
DRUGSacituzumab Govitecan-hziy
Administered intravenously
DRUGPaclitaxel
Administered intravenously
DRUGnab-Paclitaxel
Administered intravenously
DRUGGemcitabine
Administered intravenously
DRUGCarboplatin
Administered intravenously
Sponsors
Gilead Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Individuals, regardless of race and ethnic group, with previously untreated locally advanced, inoperable or metastatic triple-negative breast cancer (TNBC) * Individuals whose tumors are programmed cell death ligand 1 (PD-L1) negative at screening or individuals whose tumors are PD-L1 positive at screening if they have received an anti-PD-(L)1 inhibitor in the (neo) adjuvant setting or if they cannot be treated with a checkpoint inhibitor due to a comorbidity * Centrally confirmed TNBC and PD-L1 status on fresh or archival tissue * Individuals must have completed treatment for Stage I-III breast cancer, if indicated, and ≥ 6 months must have elapsed (with the exception of endocrine therapy) between completion of treatment with curative intent and first documented local or distant disease recurrence * Individuals presenting with de novo metastatic TNBC are eligible * Measurable disease based on computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. as evaluated locally * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Demonstrates adequate organ function * Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception * Individuals with human immunodeficiency virus (HIV) must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease Key
Exclusion criteria
* Positive serum pregnancy test or women who are lactating * Received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment * Have not recovered from adverse events (AEs) due to a previously administered agent at the time study entry * May not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible * Previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor * Active second malignancy * Active serious infection requiring antibiotics * Positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Randomization up to approximately 57 months | PFS is defined as the time from the date of randomization until the date of objective progressive disease (PD), or death (whichever comes first). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Randomization up to approximately 57 months | OS is defined as the time from the date of randomization until death due to any cause. |
| Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1 | Randomization up to approximately 57 months | ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response. |
| Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1 | Randomization up to approximately 57 months | DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of definitive PD or death from any cause (whichever comes first). |
| Time to Response (TTR) as Assessed by BICR per RECIST Version 1.1 | Randomization up to approximately 57 months | TTR is defined as the time from the date of randomization until the first documentation of CR or PR. |
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | First dose date up to approximately 57 months plus 30 days | — |
| Percentage of Participants Experiencing Clinical Laboratory Abnormalities | First dose date up to approximately 57 months plus 30 days | — |
| Change from Baseline in the Physical Functioning Domain as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core Questionnaire, Version 3.0 (EORTC QLQ-C30). | Randomization up to approximately 57 months | The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) to assess 15 scales; 1 global health status/quality of life (QOL), 5 functional scales (physical, role, cognitive, emotional, and social), and 9 symptom/item scales(fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of function, a high score for the global health status/QOL represents a high QOL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
| Time to Deterioration (TTD) of Fatigue Scale of the EORTC QLQ-C30 | Randomization up to approximately 57 months | TTD is defined as the time between the date of randomization and the date of assessment at which a patient experienced a deterioration (≥ 10 points deterioration from baseline in the fatigue scale) or death. |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Poland, Romania, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States
Contacts
STUDY_DIRECTORGilead Study Director
Gilead Sciences
Outcome results
None listed